Zydus Lifesciences Launches India's First Indigenous Aflibercept Biosimilar ANYRA
Zydus Lifesciences launched ANYRA, India's first indigenously developed aflibercept biosimilar, on February 19, 2026, following an agreement with Regeneron Pharmaceuticals and Bayer for multiple ophthalmic indications.
Zydus Lifesciences Limited launched ANYRA™, India's first indigenously developed Aflibercept 2 mg biosimilar, on February 19, 2026. The commercial launch is announced following an agreement with the drug's patent owner Regeneron Pharmaceuticals, and Bayer, according to a company release which did not disclose the deal financial terms.
Zydus will market the drug under the brand name Anyra over multiple ophthalmic indication including Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME) and others.
Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor, that helps stop the growth of abnormal blood vessels, by blocking VEGF– a signalling protein—reduce swelling, leakage, and further damage.
In 2025, Regeneron the US commercial rights holder aflibercept brand Eylea reported net sales of over $4.3 billion, down 27 per cent from the previous year, as the drug encountered impact of emerging biosimilar competition.
Last year, Bengaluru-based Biocon Biologics also signed a settlement and licensing agreement with Regeneron, clearing the US market entry for its brand Yesafili (aflibercept-jbvf), an interchangeable biosimilar of Eylea (aflibercept). Alongside them, Hyderabad-based Aurobindo Pharma's biosimilars arm, CuraTeQ Biologics, is also developing an aflibercept biosimilar, which is currently in the Phase 3 clinical stage.